Forest Laboratories Articles
Forest/Cypress' fibromyalgia drug cleared in USA
26 January 2009
Pierre Fabre teams with Forest for CNS drug
12 January 2009
Forest gets unsolicited mini-tender offer
15 December 2008
Lundbeck's 3rd-qtr 2008 net profit drops 11%
24 November 2008
Almirall's nine-month profit jumps 5.3%
24 November 2008
Forest Labs' profit up 8% on AD drug sales
10 November 2008
Forest's ceftaroline non-inferior to vancomycin/aztreonam
3 November 2008
Almirall defies critics to progress COPD drug
27 October 2008
FDA delays decison on Forest/Cypress' milnacipran
27 October 2008
Forest and Richter report on bipolar trial
6 October 2008
Almirall tumbles 42% as COPD drug disappoints
15 September 2008
Namenda ER boosts cognitive performance
11 August 2008
Forest's EPS falls to $0.79 in 2nd-qtr 2008
4 August 2008
Almirall/Forest complete COPD trials
14 July 2008
Positive Ph III data for Forest's MRSA drug
30 June 2008
Pfizer appoints Charles Triano to svp
16 June 2008
Almirall reports Ph II data for COPD drug
2 June 2008
Forest takes $44M hit on ending Azor deal
19 May 2008
Forest to apply for Lexapro in adolscents
19 May 2008
Forest Labs swings back to profit in fiscal 1st-qtr
21 April 2008
Positive Ph IIb data for Microbio/Forest's linaclotide
17 March 2008
Mylan and Forest amend Bystolic deal
10 March 2008
Forest/Cypress submit NDA for milnacipram
3 March 2008
Forest's 28mg dose ER memantine impresses
14 February 2008
US physician survey finds big differences in Rx patterns between cardiologists and PCPs
4 February 2008
Novexel and Forest sign NXL104 deal
28 January 2008
Lexapro and Namenda help Forest's income for fiscal 3rd-qtr soar 21%, beating estimates
21 January 2008
Barr confirms Namenda patent challenge
21 January 2008
Forest and Cypress file milnacipran for FMS
7 January 2008
US FDA clears Watson's generic Combunox
3 December 2007
Forest's EPS drops 5% on Microbia charge
29 October 2007
Daiichi Sankyo and Forest finalize Azor co-promotion deal
22 October 2007
Callisto moves forward with guanilib in GI
15 October 2007
US Apeals Court upholds Lexapro patent decision
10 September 2007
Japan stock market week to September 3, 2007
10 September 2007
Daiichi Sankyo and Forest sign US promotion deal
3 September 2007
Forest expands share repurchase program
20 August 2007
Forest's income for fiscal 1st qtr soars 34%
23 July 2007
SSRIs lower BMD in men and women
2 July 2007
Lundbeck drops 9% as stroke drug fails Ph III
11 June 2007
Strong early Ph III data for milnacipran
28 May 2007
Japan stock market week to May 21, 2007
28 May 2007
Forest records $238M loss for fiscal 4th-qtr
7 May 2007
Almirall sees growth from new drugs
5 March 2007
Forest Labs terminates faropenem deal with Replidyne
12 February 2007
Isis Pharma recruits Jeffrey Jonas as exec VP
5 February 2007
Forest Labs 4th-qtr profit jumps 28%
29 January 2007
Forest to buy Cerexa for $480 million in cash
22 December 2006
Targacept's TRIDMAC improves on Celexa
20 November 2006
Mylan sees profit for 2nd-qtr more than double
13 November 2006
Forest/Paion's desmatoplase trial continues
6 November 2006
Stock Commentary - New York week to Oct 23, 2006
30 October 2006
Forest reports EPS of $0.75 in 2nd-qtr 2007
23 October 2006
H Lundbeck' 2nd-qtr profits fall 69%
28 August 2006
Stock Commentary - New York week to July 24, 2006
24 July 2006
Forest Lab's 1st-qtr net revenues leap 15%
24 July 2006
Final US approval for Teva's generic Lexapro
29 May 2006
Richter/Forest's RGH-188 drug passes Ph I
22 May 2006
H Lundbeck's 2005 net profits down 6%
27 March 2006
Forest/Cypress to start third Ph III milnacipran trial
9 January 2006
Forest Labs and Richter Gedeon expand CNS accord
5 December 2005
Stock Commentary - New York week to Aug 15
5 September 2005
Sankyo's 1st-qtr sales and earnings dip
22 August 2005
Aricept and Aciphex lead Eisai's growth
15 August 2005
Forest debuts mouth ulcer spray in UK
4 July 2005
Forest Labs' sales hit by Celexa competition
25 April 2005
Forest's Campral is safe and well-tolerated
25 April 2005
Forest Labs cuts earnings forecast
11 April 2005
Forest Labs debuts Combunox in USA
28 March 2005
Correction
14 March 2005
Forest hit with second appro letter for Lexapro
7 March 2005
Aricept boosts Eisai's nine month results
28 February 2005
Forest Labs starts Ph IIb/III trial of stroke drug
21 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
Forest launch Campral in the USA
24 January 2005
Forest disappoints, despite 17% EPS hike
24 January 2005
Expanded use of Namenda on track
22 November 2004
Eisai 1st-half sales on target, rising 5.3%
15 November 2004
Forest's lercanidipine disappoints in trial
8 November 2004
Merck KGaA's 3rd-qtr profit leaps 43%
1 November 2004
Forest beats 2nd-qtr targets; raises outlook
25 October 2004
Forest appoints Francis Perier as senior vice president, finance
11 October 2004
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
